阿托伐他汀联合美金刚治疗中重度阿尔茨海默病的疗效和安全性  

Effect and safety of atrovastatin combined with memantine with moderate to severe Alzheimer's disease

作　　者：赵晓玲[1] 刘艳[1] 张仲[1] 曾仲[1] 高励[1] 杨训永[1] 邓茜[1] 朱曦[1] 

机构地区：[1]成都市第三人民医院神经内科,成都610031

出　　处：《中国实用神经疾病杂志》2010年第21期9-11,共3页Chinese Journal of Practical Nervous Diseases

摘　　要：目的探讨阿托伐他汀联合美金刚治疗中重度老年性痴呆患者的疗效及安全性。方法将52例中重度老年性痴呆患者随机分为联合用药组(阿托伐他汀联合美金刚)和美金刚组。在治疗前和治疗24周后分别进行血脂水平、简易精神状态量表(MMSE)、日常生活能力量表(ADL)及全面衰退量表(GDS)的检测和评分,并进行比较。结果联合用药组治疗前、后的血脂水平差异有统计学意义(P<0.05),而美金刚组差异无统计学意义(P>0.05)。每组治疗前、后的MMSE、ADL及GDS评分比较,差异均有统计学意义(P<0.05),而2组治疗后的各项评分比较,差异有统计学意义(P<0.05)。结论阿托伐他汀联合美金刚能有效改善中重度老年性痴呆患者的认知功能和日常生活能力,效果优于单独使用美金刚,且安全性高。Objective To explore the efficacy and safety of atrovastatin combined with memantine on patients with moderate to severe Alzheimer＇s disease. Methods Fifty-two patients with moderate to severe Alzheimer＇s disease were randomly divided into combination （atrovstatin combined with memantine） group and memantine group. The indices of TC, LDL-C, HDL- C, as well as the scores of MMSE, ADL and GDS were compared respectively between the two groups before and after treatment. Results The improvements in the indices of TC,TG,LCL-C, HDL-C and the scores of MMSE, ADL and GDS were significantly greater in the combination group than those in the memantine group statistically（P〈0.05）. Conclusion Memantine can improve effectively the cognitive and daily living skills of moderate to severe Alzheimer＇s disease. The combination of atrovstatin is superior to its single use with a higher safety.

关 键 词：美金刚 阿托伐他汀 阿尔茨海默病 痴呆 

分 类 号：R749.16[医药卫生—神经病学与精神病学]